Navigation Links
Amgen Outlines Strategy, Growth Objectives and Capital Allocation Plans
Date:4/21/2011

hat the presentation of these non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses these non-GAAP financial measures in connection with its own budgeting and financial planning. These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in conformity with GAAP. The determination of the amounts that are excluded from these non-GAAP financial measures is a matter of management judgment and depends upon, among other factors, the nature of the underlying expense or income amounts recognized in a given period. We are unable to present a quantitative reconciliation of the aforementioned forward-looking non-GAAP financial measures to their most directly comparable forward-looking GAAP financial measures because management cannot reliably predict all of the necessary components of such GAAP measures. Historically, management has excluded the following items from certain of these non-GAAP financial measures, and such items may also be excluded in future periods and could be significant in amount:

  • Expenses related to the acquisition of other businesses, including amortization and / or impairment of acquired intangible assets, integration costs, severance and retention costs and transaction costs;
  • The impact of certain accounting changes, including accounting for stock options and certain convertible debt;
  • Charges associated with restructuring and cost saving initiatives, including but not limited to asset impairments, accelerated depreciation, severance costs and lease abandonment charges;
  • Asset impairment charges and inventory write-offs;
  • Legal settlements or awards;
  • The tax effect of the above items; and
  • Non-routine settlements with tax authorities.

About Amgen

Amgen discovers, develops, manuf
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)
2. Amgen’s First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion
3. Amgen to Webcast 2011 Business Review Meeting on April 21
4. Amgen Announces Webcast of 2011 First Quarter Financial Results
5. Amgen Establishes Commercial Operations in Brazil
6. Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe
7. Amgen Donates $1 Million to Help Japanese Disaster Victims
8. Amgen Completes Acquisition of BioVex
9. NBPTS and Amgen Foundation Join to Bolster Science Education
10. Amgen to Present at the Citi 2011 Global Healthcare Conference
11. CURE Magazine Teams Up With Amgen Oncology and Breakaway from Cancer® to Launch 2011 Extraordinary Healer Award for Oncology Nursing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation ... announced that it has received commitments from institutional ... million of the Company,s common stock in an ... health care fund. The Company entered ... to which the Company agreed to sell an ...
(Date:1/15/2014)... -- BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ... Ltd (NYSE: TEVA ) and its subsidiaries ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ... VSRNAs are of molecular size less than 10 bps, ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... RALEIGH, N.C., Feb. 17, 2011 BioDelivery Sciences International, ... enrollment of its Phase 3 trial assessing the efficacy ... moderate to severe chronic pain is on schedule, with ... (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) "We are very pleased ...
... Feb. 17, 2011 Reportlinker.com announces ... is available in its catalogue: ... - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones ... http://www.reportlinker.com/p0397051/Anti-Bacterials-Market-to-2016---Cephalosporins-Penicillins-Macrolides-and-Fluoroquinolones-to-Drive-the-Anti-Bacterials-Market.html ...
Cached Medicine Technology:BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule 2BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule 3Reportlinker Adds Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market 2Reportlinker Adds Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Fla., July 31 Sky Development Inc.,announces that ... of the first of two Class A medical ... Center at 2201 North University Drive,Pembroke Pines, Florida ... The medical/professional office complex, with smart building technology,and ...
... may represent an increased risk of developing cardiovascular disease, ... academic journal Atherosclerosis , has now led to ... , Atherosclerosis (hardening of the arteries) is an inflammatory ... are thickened and become less elastic. It can cause ...
... 31 Affiliated Computer Services,Inc. (NYSE: ACS ... $100,million, with UMass Memorial Health Care, Inc., a ... The contract will extend an existing six-year business,relationship., ... will provide a cost-effective,method of expanding UMass Memorial,s ...
... with the Most Cost-Effective 2-3 Year,Plan for Achieving ... HATBORO, Pa., July 31 InfoLogix, Inc.,(Nasdaq: ... mobility and,advanced wireless asset tracking solutions for the ... launched a new Strategic,Mobility Assessment Service for hospitals ...
... Miami Herald providing online readers with a fully-branded implementation of ... ... Miami, FL (PRWEB) July 31, 2008 -- HealthCare.com, Inc. ... today announced a partnership whereby The Miami Herald Media Company, ...
... Nutraceutical,International Corporation (Nasdaq: NUTR ) today reported results ... Net sales for the fiscal,2008 third quarter were $40.5 ... fiscal 2007. For the third quarter of fiscal 2008, ... share, compared to,net income of $2.9 million, or $0.25 ...
Cached Medicine News:Health News:50% Pre-Leased at Park Plaza Professional Center in Pembroke Pines 2Health News:New discovery may lead to immunization against cardiovascular disease 2Health News:ACS Signs Five-Year, $100 Million Deal to Provide Technology Services to UMass Memorial Health Care, Inc. 2Health News:ACS Signs Five-Year, $100 Million Deal to Provide Technology Services to UMass Memorial Health Care, Inc. 3Health News:InfoLogix Launches Strategic Mobility Assessment Service for Hospitals 2Health News:InfoLogix Launches Strategic Mobility Assessment Service for Hospitals 3Health News:HealthCare.com Adds The Miami Herald to its Care Provider Search™ Network 2Health News:HealthCare.com Adds The Miami Herald to its Care Provider Search™ Network 3Health News:Nutraceutical Reports Q3 Results 2Health News:Nutraceutical Reports Q3 Results 3Health News:Nutraceutical Reports Q3 Results 4Health News:Nutraceutical Reports Q3 Results 5Health News:Nutraceutical Reports Q3 Results 6
CDIs Chin Support Bandage is ideal for Submental Liposuction, Chin Implants and all other facial procedures requiring support. Adjustable Velcro® top and posterior band secures placement....
Four way compression with five contact closures...
Applies pressure on scalp to stretch it before surgery...
Facial Mask...
Medicine Products: